Psoriatic Arthritis Therapeutics Market 2028 By Drug Class, Route of Administration, Distribution Channel, and Geography | The Insight Partners

    Psoriatic Arthritis Therapeutics Market Forecast to 2028 - Covid-19 Impact and Global Analysis - By Drug Class (Interleukin Inhibitors, PDE4 Inhibitors, TNF Inhibitors, and Other Drug Classes); Route of Administration (Oral, Parenteral and Topical); Distribution Channel (Online Pharmacies, Hospitals Pharmacies and Retail Pharmacies), and Geography

    Report Code: TIPRE00004414 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

    MARKET INTRODUCTION


    Psoriatic arthritis refers to the type of arthritis, which develops in some people with the skin condition psoriasis. The condition leads to inflammation of joints, causing inflammation, stiffness and pain. Other than inflamed joints, psoriatic arthritis also causes inflammation of the skin. Some of the symptoms of psoriatic arthritis include ankylosing spondylitis, reactive arthritis, and arthritis associated with Crohn's disease and ulcerative colitis.

    MARKET DYNAMICS


    The psoriatic arthritis therapeutics market is anticipated to grow in the forecast, owing to adoption of biologics for the treatment of psoriatic arthritis and large patient population having unmet medical needs. In addition, the improvement in healthcare facilities offered in the developing economies is expected to offer significant growth opportunities in the market during the forecast period.

    MARKET SCOPE


    The "Global Psoriatic Arthritis Therapeutics Market Analysis to 2028" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of psoriatic arthritis therapeutics market with detailed market segmentation by drug class, route of administration, distribution channel, and geography. The global psoriatic arthritis therapeutics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading psoriatic arthritis therapeutics market players and offers key trends and opportunities in the market.

    MARKET SEGMENTATION


    The global psoriatic arthritis therapeutics market is segmented on the basis of drug class, route of administration and distribution channel. Based on drug class, the market is segmented as, interleukin inhibitors, PDE4 inhibitors, TNF inhibitors, and other drug classes. The psoriatic arthritis therapeutics market is categorized based on route of administration such as oral, parenteral and topical. Similarly, based on distribution channel, the market is categorized such as, online pharmacies, hospitals pharmacies and retail pharmacies.

    Get more information on this report :

    REGIONAL FRAMEWORK


    The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global psoriatic arthritis therapeutics market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The psoriatic arthritis therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

    The report analyzes factors affecting psoriatic arthritis therapeutics market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the psoriatic arthritis therapeutics market in these regions.


    Get more information on this report :

    MARKET PLAYERS


    The reports cover key developments in the psoriatic arthritis therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from psoriatic arthritis therapeutics market are anticipated to lucrative growth opportunities in the future with the rising demand for psoriatic arthritis therapeutics market in the global market. Below mentioned is the list of few companies engaged in the psoriatic arthritis therapeutics market.

    The report also includes the profiles of key psoriatic arthritis therapeutics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
    • AbbVie Inc.
    • Amgen Inc.
    • Biogen
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • Eli Lilly and Company
    • Janssen Global Services, LLC ((Johnson & Johnson)
    • Novartis AG
    • Pfizer Inc.
    • UCB S.A.
    The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

    Get more information on this report :

    TABLE OF CONTENTS

    1. INTRODUCTION
    1.1. SCOPE OF THE STUDY
    1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
    1.3. MARKET SEGMENTATION
    1.3.1 Psoriatic Arthritis Therapeutics Market - By Drug Class
    1.3.2 Psoriatic Arthritis Therapeutics Market - By Route of Administration
    1.3.3 Psoriatic Arthritis Therapeutics Market - By Distribution Channel
    1.3.4 Psoriatic Arthritis Therapeutics Market - By Region
    1.3.4.1 By Country
    2. KEY TAKEWAYS
    3. RESEARCH METHODOLOGY
    4. PSORIATIC ARTHRITIS THERAPEUTICS MARKET LANDSCAPE
    4.1. OVERVIEW
    4.2. PEST ANALYSIS
    4.2.1 North America - Pest Analysis
    4.2.2 Europe - Pest Analysis
    4.2.3 Asia-Pacific - Pest Analysis
    4.2.4 Middle East and Africa - Pest Analysis
    4.2.5 South and Central America - Pest Analysis
    4.3. EXPERT OPINIONS
    5. PSORIATIC ARTHRITIS THERAPEUTICS MARKET - KEY MARKET DYNAMICS
    5.1. KEY MARKET DRIVERS
    5.2. KEY MARKET RESTRAINTS
    5.3. KEY MARKET OPPORTUNITIES
    5.4. FUTURE TRENDS
    5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
    6. PSORIATIC ARTHRITIS THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS
    6.1. PSORIATIC ARTHRITIS THERAPEUTICS - GLOBAL MARKET OVERVIEW
    6.2. PSORIATIC ARTHRITIS THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2028
    6.3. MARKET POSITIONING/MARKET SHARE
    7. PSORIATIC ARTHRITIS THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
    7.1. OVERVIEW
    7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
    7.3. INTERLEUKIN INHIBITORS
    7.3.1. Overview
    7.3.2. Interleukin Inhibitors Market Forecast and Analysis
    7.4. PDE4 INHIBITORS
    7.4.1. Overview
    7.4.2. PDE4 Inhibitors Market Forecast and Analysis
    7.5. TNF INHIBITORS
    7.5.1. Overview
    7.5.2. TNF Inhibitors Market Forecast and Analysis
    7.6. OTHER DRUG CLASSES
    7.6.1. Overview
    7.6.2. Other Drug Classes Market Forecast and Analysis
    8. PSORIATIC ARTHRITIS THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - ROUTE OF ADMINISTRATION
    8.1. OVERVIEW
    8.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
    8.3. ORAL
    8.3.1. Overview
    8.3.2. Oral Market Forecast and Analysis
    8.4. PARENTERAL
    8.4.1. Overview
    8.4.2. Parenteral Market Forecast and Analysis
    8.5. TOPICAL
    8.5.1. Overview
    8.5.2. Topical Market Forecast and Analysis
    9. PSORIATIC ARTHRITIS THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
    9.1. OVERVIEW
    9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
    9.3. ONLINE PHARMACIES
    9.3.1. Overview
    9.3.2. Online Pharmacies Market Forecast and Analysis
    9.4. HOSPITALS PHARMACIES
    9.4.1. Overview
    9.4.2. Hospitals Pharmacies Market Forecast and Analysis
    9.5. RETAIL PHARMACIES
    9.5.1. Overview
    9.5.2. Retail Pharmacies Market Forecast and Analysis
    10. PSORIATIC ARTHRITIS THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
    10.1. NORTH AMERICA
    10.1.1 North America Psoriatic Arthritis Therapeutics Market Overview
    10.1.2 North America Psoriatic Arthritis Therapeutics Market Forecasts and Analysis
    10.1.3 North America Psoriatic Arthritis Therapeutics Market Forecasts and Analysis - By Drug Class
    10.1.4 North America Psoriatic Arthritis Therapeutics Market Forecasts and Analysis - By Route of Administration
    10.1.5 North America Psoriatic Arthritis Therapeutics Market Forecasts and Analysis - By Distribution Channel
    10.1.6 North America Psoriatic Arthritis Therapeutics Market Forecasts and Analysis - By Countries
    10.1.6.1 United States Psoriatic Arthritis Therapeutics Market
    10.1.6.1.1 United States Psoriatic Arthritis Therapeutics Market by Drug Class
    10.1.6.1.2 United States Psoriatic Arthritis Therapeutics Market by Route of Administration
    10.1.6.1.3 United States Psoriatic Arthritis Therapeutics Market by Distribution Channel
    10.1.6.2 Canada Psoriatic Arthritis Therapeutics Market
    10.1.6.2.1 Canada Psoriatic Arthritis Therapeutics Market by Drug Class
    10.1.6.2.2 Canada Psoriatic Arthritis Therapeutics Market by Route of Administration
    10.1.6.2.3 Canada Psoriatic Arthritis Therapeutics Market by Distribution Channel
    10.1.6.3 Mexico Psoriatic Arthritis Therapeutics Market
    10.1.6.3.1 Mexico Psoriatic Arthritis Therapeutics Market by Drug Class
    10.1.6.3.2 Mexico Psoriatic Arthritis Therapeutics Market by Route of Administration
    10.1.6.3.3 Mexico Psoriatic Arthritis Therapeutics Market by Distribution Channel
    10.2. EUROPE
    10.2.1 Europe Psoriatic Arthritis Therapeutics Market Overview
    10.2.2 Europe Psoriatic Arthritis Therapeutics Market Forecasts and Analysis
    10.2.3 Europe Psoriatic Arthritis Therapeutics Market Forecasts and Analysis - By Drug Class
    10.2.4 Europe Psoriatic Arthritis Therapeutics Market Forecasts and Analysis - By Route of Administration
    10.2.5 Europe Psoriatic Arthritis Therapeutics Market Forecasts and Analysis - By Distribution Channel
    10.2.6 Europe Psoriatic Arthritis Therapeutics Market Forecasts and Analysis - By Countries
    10.2.6.1 Germany Psoriatic Arthritis Therapeutics Market
    10.2.6.1.1 Germany Psoriatic Arthritis Therapeutics Market by Drug Class
    10.2.6.1.2 Germany Psoriatic Arthritis Therapeutics Market by Route of Administration
    10.2.6.1.3 Germany Psoriatic Arthritis Therapeutics Market by Distribution Channel
    10.2.6.2 France Psoriatic Arthritis Therapeutics Market
    10.2.6.2.1 France Psoriatic Arthritis Therapeutics Market by Drug Class
    10.2.6.2.2 France Psoriatic Arthritis Therapeutics Market by Route of Administration
    10.2.6.2.3 France Psoriatic Arthritis Therapeutics Market by Distribution Channel
    10.2.6.3 Italy Psoriatic Arthritis Therapeutics Market
    10.2.6.3.1 Italy Psoriatic Arthritis Therapeutics Market by Drug Class
    10.2.6.3.2 Italy Psoriatic Arthritis Therapeutics Market by Route of Administration
    10.2.6.3.3 Italy Psoriatic Arthritis Therapeutics Market by Distribution Channel
    10.2.6.4 Spain Psoriatic Arthritis Therapeutics Market
    10.2.6.4.1 Spain Psoriatic Arthritis Therapeutics Market by Drug Class
    10.2.6.4.2 Spain Psoriatic Arthritis Therapeutics Market by Route of Administration
    10.2.6.4.3 Spain Psoriatic Arthritis Therapeutics Market by Distribution Channel
    10.2.6.5 United Kingdom Psoriatic Arthritis Therapeutics Market
    10.2.6.5.1 United Kingdom Psoriatic Arthritis Therapeutics Market by Drug Class
    10.2.6.5.2 United Kingdom Psoriatic Arthritis Therapeutics Market by Route of Administration
    10.2.6.5.3 United Kingdom Psoriatic Arthritis Therapeutics Market by Distribution Channel
    10.3. ASIA-PACIFIC
    10.3.1 Asia-Pacific Psoriatic Arthritis Therapeutics Market Overview
    10.3.2 Asia-Pacific Psoriatic Arthritis Therapeutics Market Forecasts and Analysis
    10.3.3 Asia-Pacific Psoriatic Arthritis Therapeutics Market Forecasts and Analysis - By Drug Class
    10.3.4 Asia-Pacific Psoriatic Arthritis Therapeutics Market Forecasts and Analysis - By Route of Administration
    10.3.5 Asia-Pacific Psoriatic Arthritis Therapeutics Market Forecasts and Analysis - By Distribution Channel
    10.3.6 Asia-Pacific Psoriatic Arthritis Therapeutics Market Forecasts and Analysis - By Countries
    10.3.6.1 Australia Psoriatic Arthritis Therapeutics Market
    10.3.6.1.1 Australia Psoriatic Arthritis Therapeutics Market by Drug Class
    10.3.6.1.2 Australia Psoriatic Arthritis Therapeutics Market by Route of Administration
    10.3.6.1.3 Australia Psoriatic Arthritis Therapeutics Market by Distribution Channel
    10.3.6.2 China Psoriatic Arthritis Therapeutics Market
    10.3.6.2.1 China Psoriatic Arthritis Therapeutics Market by Drug Class
    10.3.6.2.2 China Psoriatic Arthritis Therapeutics Market by Route of Administration
    10.3.6.2.3 China Psoriatic Arthritis Therapeutics Market by Distribution Channel
    10.3.6.3 India Psoriatic Arthritis Therapeutics Market
    10.3.6.3.1 India Psoriatic Arthritis Therapeutics Market by Drug Class
    10.3.6.3.2 India Psoriatic Arthritis Therapeutics Market by Route of Administration
    10.3.6.3.3 India Psoriatic Arthritis Therapeutics Market by Distribution Channel
    10.3.6.4 Japan Psoriatic Arthritis Therapeutics Market
    10.3.6.4.1 Japan Psoriatic Arthritis Therapeutics Market by Drug Class
    10.3.6.4.2 Japan Psoriatic Arthritis Therapeutics Market by Route of Administration
    10.3.6.4.3 Japan Psoriatic Arthritis Therapeutics Market by Distribution Channel
    10.3.6.5 South Korea Psoriatic Arthritis Therapeutics Market
    10.3.6.5.1 South Korea Psoriatic Arthritis Therapeutics Market by Drug Class
    10.3.6.5.2 South Korea Psoriatic Arthritis Therapeutics Market by Route of Administration
    10.3.6.5.3 South Korea Psoriatic Arthritis Therapeutics Market by Distribution Channel
    10.4. MIDDLE EAST AND AFRICA
    10.4.1 Middle East and Africa Psoriatic Arthritis Therapeutics Market Overview
    10.4.2 Middle East and Africa Psoriatic Arthritis Therapeutics Market Forecasts and Analysis
    10.4.3 Middle East and Africa Psoriatic Arthritis Therapeutics Market Forecasts and Analysis - By Drug Class
    10.4.4 Middle East and Africa Psoriatic Arthritis Therapeutics Market Forecasts and Analysis - By Route of Administration
    10.4.5 Middle East and Africa Psoriatic Arthritis Therapeutics Market Forecasts and Analysis - By Distribution Channel
    10.4.6 Middle East and Africa Psoriatic Arthritis Therapeutics Market Forecasts and Analysis - By Countries
    10.4.6.1 South Africa Psoriatic Arthritis Therapeutics Market
    10.4.6.1.1 South Africa Psoriatic Arthritis Therapeutics Market by Drug Class
    10.4.6.1.2 South Africa Psoriatic Arthritis Therapeutics Market by Route of Administration
    10.4.6.1.3 South Africa Psoriatic Arthritis Therapeutics Market by Distribution Channel
    10.4.6.2 Saudi Arabia Psoriatic Arthritis Therapeutics Market
    10.4.6.2.1 Saudi Arabia Psoriatic Arthritis Therapeutics Market by Drug Class
    10.4.6.2.2 Saudi Arabia Psoriatic Arthritis Therapeutics Market by Route of Administration
    10.4.6.2.3 Saudi Arabia Psoriatic Arthritis Therapeutics Market by Distribution Channel
    10.4.6.3 U.A.E Psoriatic Arthritis Therapeutics Market
    10.4.6.3.1 U.A.E Psoriatic Arthritis Therapeutics Market by Drug Class
    10.4.6.3.2 U.A.E Psoriatic Arthritis Therapeutics Market by Route of Administration
    10.4.6.3.3 U.A.E Psoriatic Arthritis Therapeutics Market by Distribution Channel
    10.5. SOUTH AND CENTRAL AMERICA
    10.5.1 South and Central America Psoriatic Arthritis Therapeutics Market Overview
    10.5.2 South and Central America Psoriatic Arthritis Therapeutics Market Forecasts and Analysis
    10.5.3 South and Central America Psoriatic Arthritis Therapeutics Market Forecasts and Analysis - By Drug Class
    10.5.4 South and Central America Psoriatic Arthritis Therapeutics Market Forecasts and Analysis - By Route of Administration
    10.5.5 South and Central America Psoriatic Arthritis Therapeutics Market Forecasts and Analysis - By Distribution Channel
    10.5.6 South and Central America Psoriatic Arthritis Therapeutics Market Forecasts and Analysis - By Countries
    10.5.6.1 Brazil Psoriatic Arthritis Therapeutics Market
    10.5.6.1.1 Brazil Psoriatic Arthritis Therapeutics Market by Drug Class
    10.5.6.1.2 Brazil Psoriatic Arthritis Therapeutics Market by Route of Administration
    10.5.6.1.3 Brazil Psoriatic Arthritis Therapeutics Market by Distribution Channel
    10.5.6.2 Argentina Psoriatic Arthritis Therapeutics Market
    10.5.6.2.1 Argentina Psoriatic Arthritis Therapeutics Market by Drug Class
    10.5.6.2.2 Argentina Psoriatic Arthritis Therapeutics Market by Route of Administration
    10.5.6.2.3 Argentina Psoriatic Arthritis Therapeutics Market by Distribution Channel
    11. INDUSTRY LANDSCAPE
    11.1. MERGERS AND ACQUISITIONS
    11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
    11.3. NEW PRODUCT LAUNCHES
    11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
    12. PSORIATIC ARTHRITIS THERAPEUTICS MARKET, KEY COMPANY PROFILES
    12.1. ABBVIE INC.
    12.1.1. Key Facts
    12.1.2. Business Description
    12.1.3. Products and Services
    12.1.4. Financial Overview
    12.1.5. SWOT Analysis
    12.1.6. Key Developments
    12.2. AMGEN INC.
    12.2.1. Key Facts
    12.2.2. Business Description
    12.2.3. Products and Services
    12.2.4. Financial Overview
    12.2.5. SWOT Analysis
    12.2.6. Key Developments
    12.3. BIOGEN
    12.3.1. Key Facts
    12.3.2. Business Description
    12.3.3. Products and Services
    12.3.4. Financial Overview
    12.3.5. SWOT Analysis
    12.3.6. Key Developments
    12.4. BRISTOL-MYERS SQUIBB COMPANY
    12.4.1. Key Facts
    12.4.2. Business Description
    12.4.3. Products and Services
    12.4.4. Financial Overview
    12.4.5. SWOT Analysis
    12.4.6. Key Developments
    12.5. CELGENE CORPORATION
    12.5.1. Key Facts
    12.5.2. Business Description
    12.5.3. Products and Services
    12.5.4. Financial Overview
    12.5.5. SWOT Analysis
    12.5.6. Key Developments
    12.6. ELI LILLY AND COMPANY
    12.6.1. Key Facts
    12.6.2. Business Description
    12.6.3. Products and Services
    12.6.4. Financial Overview
    12.6.5. SWOT Analysis
    12.6.6. Key Developments
    12.7. JANSSEN GLOBAL SERVICES, LLC (JOHNSON & JOHNSON)
    12.7.1. Key Facts
    12.7.2. Business Description
    12.7.3. Products and Services
    12.7.4. Financial Overview
    12.7.5. SWOT Analysis
    12.7.6. Key Developments
    12.8. NOVARTIS AG
    12.8.1. Key Facts
    12.8.2. Business Description
    12.8.3. Products and Services
    12.8.4. Financial Overview
    12.8.5. SWOT Analysis
    12.8.6. Key Developments
    12.9. PFIZER INC.
    12.9.1. Key Facts
    12.9.2. Business Description
    12.9.3. Products and Services
    12.9.4. Financial Overview
    12.9.5. SWOT Analysis
    12.9.6. Key Developments
    12.10. UCB S.A.
    12.10.1. Key Facts
    12.10.2. Business Description
    12.10.3. Products and Services
    12.10.4. Financial Overview
    12.10.5. SWOT Analysis
    12.10.6. Key Developments
    13. APPENDIX
    13.1. ABOUT THE INSIGHT PARTNERS
    13.2. GLOSSARY OF TERMS
    The List of Companies

    1. AbbVie Inc.
    2. Amgen Inc.
    3. Biogen
    4. Bristol-Myers Squibb Company
    5. Celgene Corporation
    6. Eli Lilly and Company
    7. Janssen Global Services, LLC ((Johnson & Johnson)
    8. Novartis AG
    9. Pfizer Inc.
    10. UCB S. A.
    TIPRE00004414
    Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

    Get the Latest COVID-19 Analysis on this market




    Have a question?

    Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.


    Speak To Analyst
    Pricing
    • $3000
    • $4550
    • $6550
    • $8550
        GET FREE SAMPLE PDF

    Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

        Inquire for Discount